trending Market Intelligence /marketintelligence/en/news-insights/trending/um2lCe-wmZdbKkKhg4FuAg2 content esgSubNav
In This List

Innovus Pharmaceuticals undertaking 1-for-105 reverse stock split

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Innovus Pharmaceuticals undertaking 1-for-105 reverse stock split

Innovus Pharmaceuticals Inc. is implementing a 1-for-105 reverse split of its common stock.

The San Diego-based pharmaceutical company said its stock will begin trading on a split-adjusted basis on the OTCQB marketplace at the opening of trading March 18.

The reverse stock split was approved by a majority of Innovus' stockholders Feb. 22.